Opexa Therapeutics

The Woodlands, United States Founded: 2004 • Age: 22 yrs Acquired By Acer Therapeutics
Developing personalized T-cell therapies to treat autoimmune diseases, including multiple sclerosis.

About Opexa Therapeutics

Opexa Therapeutics is a Healthcare company based in The Woodlands (United States) founded in 2004, and was acquired by Acer Therapeutics in July 2017. Developing personalized T-cell therapies to treat autoimmune diseases, including multiple sclerosis. Opexa Therapeutics has raised $5.84 million across 3 funding rounds from investors including Acer Therapeutics. The company has 9 employees. Opexa Therapeutics offers products and services including Tcelna and OPX-212. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and T-Cell. Its legal entity is Opexa Therapeutics, Inc. Its competitors include Biogen, ADMA Biologics and Kymeratx; 3 of its 3 listed competitors have raised funding.

Company details

Opexa Therapeutics was established in 2004 through the merger of PharmaFrontiers and Opexa Pharmaceuticals. Patient-specific immunotherapies are developed by the company for multiple sclerosis treatment within the biotechnology sector. The leading candidate, Tcelna, is designed for Secondary Progressive Multiple Sclerosis. Operations are conducted from The Woodlands, United States, focusing on autoimmune disease applications.

Key Metrics
  • Annual Revenue
    $2.91 M (USD)
    14
    as on Dec 31, 2016
  • Net Profit
    -$7.98 M (USD)
    34
    as on Dec 31, 2016
  • EBITDA
    -$7.75 M (USD)
    34
    as on Dec 31, 2016
  • Total Equity Funding
    $5.84M (USD)

    in 3 rounds

  • Latest Funding Round
    $650K (USD), Series A

    Feb 2013

  • Investors
  • Employee Count
    9
  • Acquired by

Products & Services of Opexa Therapeutics

Opexa Therapeutics offers a comprehensive portfolio of products and services, including Tcelna and OPX-212.

Tcelna
Immunotherapy

Personalized T-cell therapy for multiple sclerosis treatment

OPX-212
Immunotherapy

Autologous T-cell therapy for neuromyelitis optica

Funding Insights of Opexa Therapeutics

Opexa Therapeutics has successfully raised a total of $5.84M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $650 thousand completed in February 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $5.84M
  • Total Rounds 3
  • Last Round Series A β€” $650,000
  • First Round $1.1M

    (Apr 2009)

All 3 funding rounds of Opexa Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2013$650,000Series A––
–
Jul 2012$4.09MSeries A––
–
Apr 2009$1.1MSeed––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Opexa Therapeutics

Opexa Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Acer Therapeutics.

All
InvestorDescriptionFounded YearDomainLocation
Treatments for ultra-rare diseases like vEDS and MSUD are developed.
1991acertx.comCambridge, United States
Premium access

Investor details for Opexa Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Opexa Therapeutics

4 dated milestones of Opexa Therapeutics across 13 years, from founding to its latest funding, stage changes and deals.

  1. Founded Opexa Therapeutics is founded.
  2. Funding First funding round of $1.1M.
  3. Funding Latest funding round, Series A, of $650K.
  4. Exit Acquired by Acer Therapeutics.

Competitors of Opexa Therapeutics

Opexa Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, ADMA Biologics and Kymeratx.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
biogen.com1978Cambridge, United States$80M1
Therapies for neurodegenerative and immunology disorders are developed.
admabiologics.com2005Ramsey, United States$17.55M498
Plasma-based biologics are developed for immune deficiency and infectious diseases.
kymeratx.com2016Cambridge, United States$197M150
Small molecule protein degraders are developed for various disorders.
Premium access

Detailed competitors of Opexa Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Opexa Therapeutics

Websites that share an audience with Opexa Therapeutics (opexatherapeutics.com).

Similar websites

Websites whose visitors overlap most with Opexa Therapeutics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
ir.kkr.com
ir.kkr.com
100%
–
worldtopinvestor.com
100%
#13,551,810View details
amttraining.com
100%
3.3K#5,661,489View details
iif.com
100%
83.7K#494,500View details
store.mortgagebankers.org
store.mortgagebankers.org
61%
–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 6 similar websites and full traffic analytics for Opexa Therapeutics

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 6 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Cell Therapy

3 companies that operate in the same segment as Opexa Therapeutics (Cell Therapy) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
2013Seattle, Washington, United StatesUSD 316.67 M520
CAR-T and TIL immunotherapies for solid tumors are developed.
2018San Francisco, California, United StatesUSD 493 MUSD 36 K233
Smart surgical devices for spinal surgery are developed.
1997San Diego, California, United StatesUSD 54.1 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Opexa Therapeutics

Premium access

Complete news archive for Opexa Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Opexa Therapeutics

Opexa Therapeutics was founded in 2004 and raised its 1st funding round 5 years after it was founded.

Opexa Therapeutics is headquartered in The Woodlands, United States. It is registered at The Woodlands, Texas, United States.

Opexa Therapeutics is a funded company, having raised a total of $5.84M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.1M, raised on Apr 2009.

Opexa Therapeutics has 9 employees.

Annual revenue of Opexa Therapeutics is $2.91M as on Dec 31, 2016.

Opexa Therapeutics was established in 2004 through the merger of PharmaFrontiers and Opexa Pharmaceuticals. Patient-specific immunotherapies are developed by the company for multiple sclerosis treatment within the biotechnology sector. The leading candidate, Tcelna, is designed for Secondary Progressive Multiple Sclerosis. Operations are conducted from The Woodlands, United States, focusing on autoimmune disease applications.

Opexa Therapeutics's top competitors include ADMA Biologics, Kymeratx and Biogen.

Opexa Therapeutics offers Tcelna and OPX-212.

Opexa Therapeutics has 1 investor. Key investors include Acer Therapeutics.

Opexa Therapeutics operates through Opexa Therapeutics, Inc..

Yes. Opexa Therapeutics was acquired by Acer Therapeutics in July 2017.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available